J9309 HCPCS code: Injection, polatuzumab vedotin-piiq, 1 mg
J9309 is the HCPCS Level II code for injection, polatuzumab vedotin-piiq, 1 mg. In 2024 Medicare paid an average of $99.06 per service for J9309 across 547,329 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 280 per day on outpatient hospital claims. Medicare volume rose 161% from 2022 to 2024 (209,652 to 547,329 services). In 2024, about 1,229 clinicians billed Medicare for J9309 for 1,045 beneficiaries; Texas, Florida, California accounted for 36% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2020-01-01 |
| Last action effective | 2020-01-01 |
Who bills J9309 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,229 |
| Medicare beneficiaries | 1,045 |
| States with claims | 29 |
| Share of services in top 3 states (Texas, Florida, California) | 36% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9309, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 209,652 | 413 | $113.51 | $90.60 |
| 2023 | 356,459 | 705 | $116.91 | $93.15 |
| 2024 | 547,329 | 1,045 | $124.34 | $99.06 |
States with the most J9309 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 70,478 | $99.66 |
| Florida | 62,889 | $99.93 |
| California | 51,732 | $99.72 |
| Illinois | 33,658 | $99.19 |
| Virginia | 23,410 | $98.94 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 280 | CMS Policy |
| practitioner claims | 280 | CMS Policy |
What changed for J9309
- 2020-01-01: J9309 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9309?
J9309 is the HCPCS Level II code for injection, polatuzumab vedotin-piiq, 1 mg. Short descriptor: "Inj, polatuzumab vedotin 1mg".
How much does Medicare pay for J9309?
In 2024, the average Medicare payment was $99.06 per service (average allowed $124.34).
Does Medicare cover J9309?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J9309 can be billed per day?
280 on outpatient hospital claims; 280 on practitioner claims (NCCI medically unlikely edits).
Related J93 codes
- J9300 — Injection, gemtuzumab ozogamicin, 5 mg
- J9301 — Injection, obinutuzumab, 10 mg
- J9302 — Injection, ofatumumab, 10 mg
- J9303 — Injection, panitumumab, 10 mg
- J9304 — Injection, pemetrexed (pemfexy), 10 mg
- J9305 — Injection, pemetrexed, not otherwise specified, 10 mg
- J9306 — Injection, pertuzumab, 1 mg
- J9307 — Injection, pralatrexate, 1 mg
- J9308 — Injection, ramucirumab, 5 mg
- J9310 — Injection, rituximab, 100 mg
- J9311 — Injection, rituximab 10 mg and hyaluronidase
- J9312 — Injection, rituximab, 10 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9309
- Watch J9309 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9309
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.